Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care reports developments in automated insulin delivery and diabetes technology. The company manufactures and sells pump systems including Tandem Mobi and the t:slim X2 insulin pump, both powered by Control-IQ+ advanced hybrid closed-loop technology. News commonly covers FDA clearances, pump and mobile-app compatibility, continuous glucose monitoring integrations, and product portfolio updates for people with diabetes.
Company updates also address quarterly and annual operating results, worldwide and U.S. sales trends, pump shipments, gross margin, financial guidance, reimbursement-model changes, investor conference presentations, and capital actions such as convertible debt financing.
Tandem Diabetes Care (Nasdaq: TNDM) will release its fourth quarter and full year 2025 financial results after market close on Thursday, February 19, 2026. The company will host a conference call and simultaneous webcast the same day at 4:30 PM ET (1:30 PM PT) to discuss financial and operating results.
Investors can access the live webcast and an archived recording (available for 30 days) via Tandem Diabetes Care’s Investor Center under “Events & Presentations.” Telephone access and dial-in details are provided after registration through the company’s listed registration link.
Tandem Diabetes Care (Nasdaq: TNDM) announced on December 18, 2025 that the Tandem t:slim mobile app is now available in Canada for Android and iOS. The app lets eligible t:slim X2 users (pump version 7.8.1+) deliver and cancel boluses from a paired smartphone, view 24-hour glucose trends, pump status, basal/bolus deliveries and suspensions, and receive pump alerts. Data can be uploaded wirelessly to the cloud-based Tandem Source platform. The t:slim X2 pump continues to operate independently, and uploads are not real-time.
Tandem Diabetes Care (Nasdaq: TNDM) announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025. Ms. Beaver joins as an independent director and will serve on the board’s Audit Committee and Cybersecurity and Data Oversight Committee. She brings more than 20 years of strategic and operational finance experience across healthcare, medical devices, enterprise technology, gaming and manufacturing. Ms. Beaver is currently CFO at Lyra Health (since June 2025) and previously served three years as CFO at Evolus, with prior senior finance roles at Experian and IGT. Her credentials include a Bachelor of Business Administration from University of Massachusetts and a Professional Designation in Relational Database Design from UCLA.
Tandem Diabetes Care (Nasdaq: TNDM) announced FDA clearance of the Android version of the Tandem Mobi mobile app, expanding compatibility to Android smartphones and extending its connected-care ecosystem.
Key facts: the app pairs with the Tandem Mobi automated insulin delivery system powered by Control-IQ+, cites outcomes including 79% time in range and 90% overnight time in range, and will begin a limited release in December 2025 with commercial availability in early 2026. Compatible devices slated to include Google Pixel 6–10 and Samsung Galaxy S21–S25; a full compatibility list will be published before launch.
Tandem Diabetes Care (Nasdaq: TNDM) reported Q3 2025 results on November 6, 2025, and reaffirmed full‑year 2025 guidance.
Key metrics: Q3 sales $249.3M worldwide with $73.6M outside the U.S.; U.S. shipments >20,000 pumps and international shipments >9,000 pumps. GAAP gross profit was $134.3M and GAAP gross margin improved to 54% from 51% year‑over‑year. GAAP net loss was $21.2M; GAAP operating loss was $22.9M (‑9% of sales). Adjusted EBITDA was $2.8M (1% of sales).
Operational progress: expanded pharmacy coverage for Tandem Mobi to >40% of U.S. lives, introduced t:slim X2 supplies via pharmacy, received FDA 510(k) for SteadiSet extended wear, filed 510(k) for Android control of Tandem Mobi, and began global rollout of t:slim X2 with FreeStyle Libre 3 Plus CGM.
Full‑year 2025 guidance: ~$1.0B sales (U.S. ~ $700M; non‑U.S. ~ $300M), gross margin ~53%–54%, and adjusted EBITDA margin ~‑5% (guidance recast to include an IPR&D charge).
Tandem Diabetes Care (Nasdaq: TNDM) announced on November 4, 2025 that it achieved ISO/IEC 27001:2022 certification from Insight Assurance, confirming a company-wide Information Security Management System (ISMS).
The certification follows a comprehensive independent audit of physical security, vendor access controls, employee training, and data management practices and is presented as strengthening Tandem’s position in regulated international markets while simplifying compliance for partners and healthcare providers.
Company leadership framed the achievement as evidence of commitment to cybersecurity, data protection, and operational integrity and provided links for multimedia and further cybersecurity information.
Tandem Diabetes Care (NASDAQ:TNDM) will present company updates at two investor conferences: the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 10:40 AM ET (7:40 AM PT), and the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:30 AM ET (7:30 AM PT).
Both presentations will be webcast live, and an archive recording will be available for 30 days. Live and archived webcasts will be accessible in the company’s Investor Center under Events & Presentations at http://investor.tandemdiabetes.com.
Tandem Diabetes Care (NASDAQ: TNDM) announced that the t:slim X2 insulin pump with Control-IQ+ automated insulin delivery is now available in the United States with integration for Abbott’s FreeStyle Libre 3 Plus CGM sensor.
The updated software is preloaded on all new U.S. t:slim X2 shipments and offered as a free remote software update to eligible existing users. Tandem plans early-access international launches before year-end 2025 and scaled commercial availability in 2026.
Key device facts: the FreeStyle Libre 3 Plus transmits glucose readings every 1 minute and offers 15-day wear; Control-IQ+ adjusts insulin every 5 minutes and includes AutoBolus to automatically calculate and deliver correction boluses.
Tandem Diabetes Care (Nasdaq: TNDM) will release its third quarter 2025 financial and operating results after market close on Thursday, November 6, 2025.
The company will host a live conference call and webcast the same day at 4:30 PM ET (1:30 PM PT). The webcast will be available at http://investor.tandemdiabetes.com in the “Events & Presentations” section. Participants can join the call by phone via the registration link provided in the press release to receive dial-in details and a personal PIN.
An archived webcast will be available for 30 days after the event on the company’s Investor Center site.
Tandem Diabetes Care (NASDAQ: TNDM) announced that its t:slim X2 insulin pump with Control-IQ+ automated insulin delivery technology has received clearance for use with Lyumjev ultra-rapid acting insulin in the United States. The approval applies to people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes.
The clearance was supported by a 13-week multicenter study involving 179 individuals, demonstrating high satisfaction and quality of life benefits. The t:slim X2 pump is now compatible with three insulin types: Humalog, Novolog, and Lyumjev U-100. Notably, Lyumjev is accessible through Lilly's Insulin Value Program at $35 monthly for those with commercial insurance or no insurance.